Article Text

PDF

Arrhythmias and interventional therapy
Analysis of left ventricular remodelling in patients treated with cardiac resynchronisation therapy
  1. Zhe An,
  2. Wenqi Zhang
  1. China-Japan Union Hospital of Jilin University

Abstract

Objective Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play a role in left ventricular structural remodelling. The aim of our study was to analyse MMP-2 and TIMP-1 levels as predictors of poor response to cardiac resynchronisation therapy (CRT).

Methods A 1-year cohort of patients who received a CRT device in our centre was included in the study. All patients underwent a 12-lead ECG, echocardiogram and clinical evaluation prior to implant and at 6- and 12-month follow-up. At the time of CRT implant, blood samples from a peripheral vein and the CS were obtained simultaneously. Serum and plasma samples were stored at −80°C until assay. Serum MMP-2 and plasma TIMP-1 levels were assessed using a commercially available sandwich enzyme immunoassay.

Results A cohort of 84 CRT patients from our centre was prospectively evaluated at baseline and after 12-month follow-up. MMP-2 and TIMP-1 assays were performed prior to CRT implant. Cardiac resynchronisation therapy responders were defined as patients who survived, not transplanted, and increased their basal 6 min walking distance test (6MWDT) by ≥10% or improved their NYHA functional class. Over all, 50 patients (60%) were classed as responders. At 12-month follow-up, 12 patients (14.2%) had died and 2 (2.4%) patient had been transplanted. Compared with responders, non-responders had higher levels of TIMP-1 (277±59 vs 216±46 ng/ml, p=0.001), MMP-2 (325±115 vs 258±56 ng/ml, p=0.02). In a multivariate analysis, TIMP-1 was the predictor of non-response to CRT (OR 0.97, 95% CI 0.96 to 0.99, p=0.005).

Conclusion TIMP-1 was an predictor of non-response in patients treated with CRT. TIMP-1 and MMP-2 were higher in patients who did not respond to CRT.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.